Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture Partners and Bristol Myers Squibb Co. With ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Patients with rheumatoid arthritis who undergo immune checkpoint inhibition for metastatic non-small cell lung cancer demonstrate similar overall survival as those without RA, according to data ...

The global keloid treatment market is on a robust growth trajectory, with an estimated value of USD 4,135.1 million in 2025. Projections indicate a substantial expansion to USD 5,975.7 million by 2035 ...

Bristol-Myers Squibb recently wrapped up a pivotal study in Japan, focusing on the quality of life in patients with ...

"BikeTown Africa," a nonprofit organization, delivered more than 200 bikes to rural Africa to provide life-saving and ...

Ninety-three percent of hospitals responding to a recent survey conducted by 340B Health said they would struggle to maintain current levels of uncompensated care in the wake of drugmakers’ proposed ...

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...